SCHEMBL4767807

SCHEMBL4767807

CS(=O)(=O)N(Cc1ccccc1Cl)c1ccc(C(=O)NCc2ccc3c(c2)OCO3)cc1

nearest known ligand 0.74

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 4/20 0.74
GAA P10253 1/20 0.65
ALDH1A1 P00352 4/20 0.61
MAPT P10636 3/20 0.61
PKM P14618 2/20 0.61
KMT2A Q03164 3/20 0.58
MEN1 O00255 2/20 0.58
TDP1 Q9NUW8 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.55
LMNA P02545 1/20 0.55
ALDH2 P05091 1/20 0.55
TP53 P04637 1/20 0.54
HSD17B10 Q99714 1/20 0.54
HSP90AA1 P07900 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4791474 0.90 ALDH1A1 (0.61) NPSR1GAAALDH1A1MAPTPKM
SCHEMBL5571868 0.85 ALDH1A1 (0.58) NPSR1ALDH1A1MAPTPKMKMT2A
SCHEMBL4768048 0.84 HPGD (0.54) NPSR1GAAALDH1A1MAPTPKM
SCHEMBL4771234 0.84 GAA (0.72) NPSR1GAAALDH1A1MAPTSMN1; SMN2
SCHEMBL5571397 0.84 ALDH1A1 (0.61) NPSR1ALDH1A1MAPTPKMKMT2A
SCHEMBL4771213 0.83 GAA (0.71) NPSR1GAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4777505 0.83 GAA (0.71) NPSR1GAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4775048 0.82 GAA (0.70) NPSR1GAAALDH1A1MAPTSMN1; SMN2
SCHEMBL4776615 0.79 GAA (0.68) NPSR1GAAALDH1A1MAPTKMT2A
SCHEMBL4768019 0.79 GAA (1.00) GAAALDH1A1KMT2AMEN1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 NPSR1 4395/4885GAA 466/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.